During the last session, Cassava Sciences Inc. (NASDAQ:SAVA)’s traded shares were 23.64 million, with the beta value of the company hitting 0.99. At the end of the trading day, the stock’s price was $52.31, reflecting an intraday loss of -1.04% or -$0.55. The 52-week high for the SAVA share is $146.16, that puts it down -179.41 from that peak though still a striking 87.19% gain since the share price plummeted to a 52-week low of $6.70. The company’s market capitalization is $1.90B, and the average intraday trading volume over the past 10 days was 5.79 million shares, and the average trade volume was 7.28 million shares over the past three months.
Cassava Sciences Inc. (SAVA) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 2.00. SAVA has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.16.
Cassava Sciences Inc. (NASDAQ:SAVA) trade information
Cassava Sciences Inc. (SAVA) registered a -1.04% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.04% in intraday trading to $52.31 this Wednesday, 09/22/21, hitting a weekly high. The stock’s 5-day price performance is 19.10%, and it has moved by -54.75% in 30 days. Based on these gigs, the overall price performance for the year is 400.57%. The short interest in Cassava Sciences Inc. (NASDAQ:SAVA) is 3.78 million shares and it means that shorts have 2.64 day(s) to cover.
The consensus price target of analysts on Wall Street is $149.20, which implies an increase of 64.94% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $108.00 and $215.00 respectively. As a result, SAVA is trading at a discount of -311.01% off the target high and -106.46% off the low.
Cassava Sciences Inc. (SAVA) estimates and forecasts
Statistics show that Cassava Sciences Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Cassava Sciences Inc. (SAVA) shares have gone up 7.17% during the last six months, with a year-to-date growth rate less than the industry average at -166.67% against 18.10. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to shrink -166.70% this quarter and then drop -133.30% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 35.40%. While earnings are projected to return 8.80% in 2021.
Cassava Sciences Inc. is due to release its next quarterly earnings between November 08 and November 12. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Cassava Sciences Inc. (NASDAQ:SAVA)’s Major holders
Cassava Sciences Inc. insiders own 6.49% of total outstanding shares while institutional holders control 27.59%, with the float percentage being 29.50%. Blackrock Inc. is the largest shareholder of the company, while 166 institutions own stock in it. As of Mar 30, 2021, the company held over 2.4 million shares (or 6.01% of all shares), a total value of $108.1 million in shares.
The next largest institutional holding, with 1.77 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 4.43% of outstanding shares. At the market price on Mar 30, 2021, these shares were valued at $79.75 million.
Also, the Mutual Funds coming in first place with the largest holdings of Cassava Sciences Inc. (SAVA) shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. Data provided on Mar 30, 2021 indicates that Vanguard Total Stock Market Index Fund owns about 1.05 million shares. This amounts to just over 2.62 percent of the company’s overall shares, with a $47.1 million market value. The same data shows that the other fund manager holds slightly less at 0.77 million, or about 1.93% of the stock, which is worth about $36.06 million.